10-K: Procept Biorobotics Reports Fiscal Year 2023 Results, Revenue Jumps 82%

Procept Biorobotics reports significant revenue growth for fiscal year 2023, driven by increased adoption of its Aquablation therapy.

Summary

• Procept Biorobotics, a surgical robotics company focused on urology, reported its fiscal year 2023 results.
• Revenue for the year reached $136.2 million, an 82% increase compared to $75.0 million in 2022.
• The company incurred a net loss of $105.9 million in 2023, compared to a net loss of $87.2 million in the previous year.
• As of December 31, 2023, Procept Biorobotics had an install base of 418 AquaBeam Robotic Systems globally, with 315 located in the United States.
• The company believes its Aquablation therapy represents a paradigm shift in the surgical treatment of BPH.
• Procept is targeting 860 high-volume hospitals in the U.S. that perform a significant portion of resective BPH procedures.
• The company is focused on driving adoption of Aquablation therapy among urologists and increasing system utilization.
• Procept is committed to building a strong base of clinical evidence to support its products.
• The company is investing in research and development to drive continuous improvements and innovation.
• Procept is working to further penetrate and expand into existing and new international markets.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth is strong and the company is expanding its market presence, continued net losses and reliance on future financing introduce uncertainty. The company's innovative technology and positive clinical data are encouraging, but the competitive landscape and regulatory hurdles remain significant challenges.

Positives

• Significant revenue growth indicates increasing market adoption of Aquablation therapy.
• Expansion of the AquaBeam Robotic System install base demonstrates growing customer demand.
• Medicare coverage provides access to a large patient population.
• Investment in R&D signals a commitment to innovation and future growth.
• Strong relationships with key opinion leaders and urological societies support broader acceptance of Aquablation therapy.

Negatives

• The company continues to incur significant net losses.
• Increased operating expenses are contributing to the net loss.
• The company relies on single-source suppliers, creating potential supply chain vulnerabilities.

Risks

• The company may need additional funding to finance its planned operations.
• The commercial success of the AquaBeam Robotic System depends on market acceptance among hospitals, surgeons, and patients.
• The company faces competition from larger companies with greater resources.
• The company has limited experience manufacturing its products in large-scale commercial quantities.
• The company is subject to extensive government regulation and oversight.
• The company must obtain, maintain, and protect its intellectual property.
• The market price of the company's common stock may be volatile.

Future Outlook

The company expects revenue to increase in absolute dollars for the foreseeable future as it continues to focus on driving adoption of Aquablation therapy and increased system utilization. The company also expects to continue to incur net losses for the foreseeable future as it continues to expand its sales and marketing organization, invest in clinical trials and registries, and research and development of product improvements and future products.

Management Comments

• The company believes that Aquablation therapy represents a paradigm shift in the surgical treatment of BPH.
• The company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from LUTS, due to BPH that is independent of prostate size and shape, and delivers resection independent of surgeon experience.

Industry Context

The medical device industry is highly competitive, with rapid changes driven by new products and technologies. Procept Biorobotics competes with pharmaceutical products and medical device companies that manufacture surgical alternatives for treating BPH, including Boston Scientific Corporation and Teleflex Incorporated.

Comparison to Industry Standards

• The WATER study is the only FDA pivotal study randomized against TURP, the historical standard of care for BPH.
• The retreatment rates in the WATER and WATER II studies compare favorably to surgical retreatment rates observed for alternative treatments for BPH, such as TURP and photoselective vaporation of the prostate (PVP).
• Aquablation therapy has demonstrated low rates of irreversible complications, including urinary incontinence, erectile dysfunction and ejaculatory dysfunction, compared to published rates observed for other resective surgeries.

Corporate Governance

Legal Proceedings

• From time to time, the company may be involved in legal proceedings arising in the ordinary course of its business.
• The company is not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on its business.

Stakeholder Impact

• Shareholders: The company's performance impacts shareholder value, with revenue growth being a positive factor and net losses being a negative factor.
• Employees: The company's growth and financial stability affect employment opportunities and compensation.
• Customers (hospitals and surgeons): The company's products and services impact the quality of care they can provide to patients.
• Patients: The company's Aquablation therapy aims to provide effective, safe, and durable outcomes for BPH patients.
• Suppliers: The company's reliance on third-party suppliers creates interdependencies and potential impacts on their businesses.

Next Steps

• Continue to grow the installed base of AquaBeam Robotic Systems.
• Increase system utilization by establishing Aquablation therapy as the surgical treatment of choice for BPH.
• Continue to broaden private payor coverage.
• Build upon the strong base of clinical evidence.
• Invest in research and development to drive continuous improvements and innovation.
• Drive increased awareness of Aquablation therapy beyond the urology community.
• Further penetrate and expand into existing and new international markets.

Key Dates

Keywords

Aquablation, BPH, Robotics, Urology, AquaBeam, Revenue, Surgical, Procept, Therapy, Medical